TABLE 3.
Overview of the affected physiological mechanisms in POR and AMA patients following KEGG analysis.
| Affected pathways | POR | AMA |
| Signaling pathways and signal transduction | ||
| PI3K-Akt signaling pathway | † | † |
| mTOR signaling pathway | † | † |
| TGF-β signaling pathway | † | |
| FoxO signaling pathway | † | |
| Wnt signaling pathway | † | |
| Hippo signaling pathway | † | |
| Ras signaling pathway | † | † |
| EGFR tyrosine kinase inhibitor resistance pathway | † | † |
| AMPK signaling pathway | † | † |
| MAPK pathway | † | † |
| p53 signaling pathway | † | † |
| N eurotrophins signaling pathway | † | † |
| ErbB(/EGFR) signaling pathway | † | † |
| JAK-STAT signaling pathway | † | † |
| Cellular functions and interactions | ||
| Regulation of actin cytoskeleton | † | † |
| Oocyte meiosis | † | |
| Apoptosis | † | |
| Cellular senescence | † | † |
| Mitophagy | † | |
| Gap junctions | † | |
| Hormonal signaling | ||
| Growth hormone synthesis, secretion and action | † | † |
| Protein Regulation | ||
| N-glycan biosynthesis | † | † |
| Glucose Metabolism | † | † |
† This symbol indicates the category of patients a certain pathway is disregulated in.